ACR Open Rheumatology最新文献

{"title":"Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.","authors":"Christopher T Ritchlin,&nbsp;Atul Deodhar,&nbsp;Wolf-Henning Boehncke,&nbsp;Enrique R Soriano,&nbsp;Alexa P Kollmeier,&nbsp;Xie L Xu,&nbsp;Federico Zazzetti,&nbsp;May Shawi,&nbsp;Yusang Jiang,&nbsp;Shihong Sheng,&nbsp;Philip S Helliwell","doi":"10.1002/acr2.11523","DOIUrl":"https://doi.org/10.1002/acr2.11523","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate efficacy and safety of the interleukin-23p19-subunit inhibitor, guselkumab, in DISCOVER-1 patients with active psoriatic arthritis (PsA) by prior use of tumor necrosis factor inhibitor (TNFi).</p><p><strong>Methods: </strong>The phase 3, randomized, placebo-controlled DISCOVER-1 study enrolled patients with active PsA (swollen joint count ≥3, tender joint count ≥3, and C-reactive protein level ≥ 0.3 mg/dl) despite standard therapies; approximately one-third could have received two or fewer prior TNFi. Patients were randomized to 100 mg of guselkumab every 4 weeks (Q4W); 100 mg of guselkumab at week 0, at week 4, and every 8 weeks (Q8W); or placebo with crossover to guselkumab Q4W at week 24. Efficacy end points of ≥20% and ≥50% improvement in individual American College of Rheumatology (ACR) criteria and achieving the minimal disease activity (MDA) components were summarized by prior TNFi status.</p><p><strong>Results: </strong>In DISCOVER-1, 118 (31%) patients previously received one or two TNFi. As previously reported, rates for acheiving ≥20% improvement in the composite ACR response at week 24 and week 52 were similar in TNFi-naive and TNFi-experienced patients randomized to guselkumab Q4W (76% and 68%, respectively) and Q8W (61% and 58%, respectively). Similar trends were observed for response rates of ≥20% and ≥50% improvement in individual ACR criteria and for achieving individual MDA components at week 24; TNFi-naive patients were more likely to achieve end points related to physical function and pain than TNFi-experienced patients. Overall, response rates were maintained or increased through week 52 regardless of prior TNFi use. Through week 60 in guselkumab-treated TNFi-naive and TNFi-experienced patients, 62% and 64%, respectively, reported one or more adverse events (AEs); 4% and 6% had serious AEs, respectively.</p><p><strong>Conclusion: </strong>Through 1 year, 100 mg of guselkumab Q4W and Q8W provided sustained improvements across multiple domains in both TNFi-naive and TNFi-experienced patients with active PsA.</p>","PeriodicalId":7084,"journal":{"name":"ACR Open Rheumatology","volume":"5 3","pages":"149-164"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/52/23/ACR2-5-149.PMC10010489.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9479459","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calcinosis universalis in systemic sclerosis.","authors":"Eaman Alhassan","doi":"10.1002/acr2.11527","DOIUrl":"https://doi.org/10.1002/acr2.11527","url":null,"abstract":"The patient, a 46-year-old woman with a history of systemic sclerosis, interstitial lung disease, and dystrophic calcinosis cutis presented to the emergency department complaining of right thigh pain. Physical examination was notable for a large erythematous, tender, indurated circular area in the medial thigh with many large calci fi ed nodules throughout her thighs. Incision and drainage yielded a small amount of purulent chalky fl uid. The patient received antibiotics and was discharged home. Over 5 years, the patient had recurrent soft tissue infections with progressive calcinosis. Her basic metabolic panel was within normal limits (including calcium and phosphorus levels). Computed tomography showed extensive calci fi cation throughout the subcutaneous tissues of the pelvis and bilateral thighs. Some of the calcinosis extended into the intermuscular fascial planes of the adductor and posterior compartment musculature of the bilateral thighs. The patient received nifedipine, mycophenolic acid, rituximab, colchicine, and sodium thiosulfate (topical, intralesional, and intrave-nous), but her calcinosis continued to progress. Calcinosis is a debilitating condition that occurs in 40% of patients with systemic sclerosis. A long disease duration is associated with progressive calcinosis (1). Thus far, there are no effective treatment options for calcinosis.","PeriodicalId":7084,"journal":{"name":"ACR Open Rheumatology","volume":"5 3","pages":"105"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/b6/ACR2-5-105.PMC10010482.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9109650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraindividual Change in Cognitive Function Among Adults With Systemic Lupus Erythematosus: A Markov Analysis Over 7 Years.","authors":"Stefan Perera,&nbsp;Richard Cook,&nbsp;Ker-Ai Lee,&nbsp;Patti Katz,&nbsp;Zahi Touma","doi":"10.1002/acr2.11529","DOIUrl":"https://doi.org/10.1002/acr2.11529","url":null,"abstract":"Cognitive impairment is prevalent in systemic lupus erythematosus (SLE). There remain gaps in understanding cognition and SLE longitudinally. We studied intraindividual change in cognition in SLE over time.","PeriodicalId":7084,"journal":{"name":"ACR Open Rheumatology","volume":"5 3","pages":"124-131"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/3e/ACR2-5-124.PMC10010484.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9164791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial and Ethnic Differences in a Biochemical Marker of Rheumatoid Arthritis Disease Activity.","authors":"Rahaf Baker,&nbsp;Bryanna Mantilla,&nbsp;Jonathan Graf,&nbsp;Patricia P Katz,&nbsp;Sarah Goglin,&nbsp;Jennifer L Barton,&nbsp;Jean W Liew,&nbsp;Katherine D Wysham","doi":"10.1002/acr2.11524","DOIUrl":"https://doi.org/10.1002/acr2.11524","url":null,"abstract":"<p><strong>Objective: </strong>Racial and ethnic disparities in rheumatoid arthritis (RA) disease activity measures have been documented. We compared racial and ethnic differences in disease activity using multiple composite measures, including an objective measure, the multi-biochemical disease activity (MBDA) score.</p><p><strong>Methods: </strong>Data are derived from the University of California, San Francisco RA Cohort, a longitudinal observational cohort. Participants with at least one MBDA measure and self-reported race and ethnicity were included. Multivariable linear regression evaluated the association between race and ethnicity groups and mean MBDA score, adjusting for potential confounders, including symptom duration and medication use. Sensitivity analyses substituted the Clinical Disease Activity Index (CDAI) and the Disease Activity Score-28 joints with erythrocyte sedimentation rate (DAS28-ESR) for the MBDA in multivariable models.</p><p><strong>Results: </strong>We included 267 participants (86% female, mean age 52.7 ± 13.3 years). The majority were Latinx (n = 137; 51%), followed by Asian (n = 91; 34%). After adjustment, Latinx participants had the highest mean MBDA score (40.6 ± 2.1) compared with White participants at (32.8 ± 6.7). Black participants had the second highest mean MBDA score, followed by Asian participants (36.3 ± 5.3, 36.0 ± 2.7, respectively), although neither were significantly different from White participants. The trends observed for the CDAI and DAS28-ESR were similar to those for the MBDA.</p><p><strong>Conclusion: </strong>We found significantly higher disease activity measured by the MBDA and DAS28-ESR in Latinx participants compared with White participants. We also found significantly higher disease activity in Asian participants compared with White participants with the DAS28-ESR. Our findings, although limited by the small number of White participants in the referent group, suggest that RA disease activity measures may be influenced by external factors that have differential impacts by racial and ethnic group.</p>","PeriodicalId":7084,"journal":{"name":"ACR Open Rheumatology","volume":"5 3","pages":"142-148"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/79/c6/ACR2-5-142.PMC10010485.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9165533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccination Rates, Perceptions, and Information Sources Used by People With Inflammatory Arthritis.","authors":"Andrea Lyon,&nbsp;Alannah Quinlivan,&nbsp;Susan Lester,&nbsp;Claire Barrett,&nbsp;Samuel L Whittle,&nbsp;Debra Rowett,&nbsp;Rachel Black,&nbsp;Premarani Sinnathurai,&nbsp;Lyn March,&nbsp;Rachelle Buchbinder,&nbsp;Catherine L Hill","doi":"10.1002/acr2.11525","DOIUrl":"https://doi.org/10.1002/acr2.11525","url":null,"abstract":"<p><strong>Objective: </strong>To determine vaccination rates, perceptions, and information sources in people with inflammatory arthritis.</p><p><strong>Methods: </strong>Participants enrolled in the Australian Rheumatology Association Database were invited to participate in an online questionnaire, conducted in January 2020, prior to the COVID-19 pandemic. Included questions were about vaccination history, modified World Health Organization Vaccination Hesitancy Scale, views of the information sources consulted, the Beliefs About Medicines Questionnaire, education, and the Single-Item Health Literacy Screener.</p><p><strong>Results: </strong>Response rate was 994 of 1498 (66%). The median age of participants was 62 years, with 67% female. Self-reported adherence was 83% for the influenza vaccine. Participants generally expressed positive vaccination views, particularly regarding safety, efficacy, and access. However, only 43% knew which vaccines were recommended for them. Vaccine hesitancy was primarily attributable to uncertainty and a perceived lack of information about which vaccines were recommended. Participants consulted multiple vaccination information sources (median 3, interquartile range 2-7). General practitioners (89%) and rheumatologists (76%) were the most frequently used information sources and were most likely to yield positive views. Negative views of vaccination were most often from internet chatrooms, social media, and mainstream media. Factors of younger age, male gender, and having more concerns about the harms and overuse of medicines in general were associated with lower adherence and greater uncertainty about vaccinations, whereas education and self-reported literacy were not.</p><p><strong>Conclusion: </strong>Participants with inflammatory arthritis generally held positive views about vaccination, although there was considerable uncertainty as to which vaccinations were recommended for them. This study highlights the need for improved consumer information about vaccination recommendations for people with inflammatory arthritis.</p>","PeriodicalId":7084,"journal":{"name":"ACR Open Rheumatology","volume":"5 2","pages":"84-92"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10791989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptome Profiling of Immune Cell Types in Peripheral Blood Reveals Common and Specific Pathways Involved in the Pathogenesis of Myositis-Specific Antibody-Positive Inflammatory Myopathies.","authors":"Yusuke Sugimori,&nbsp;Yukiko Iwasaki,&nbsp;Yusuke Takeshima,&nbsp;Mai Okubo,&nbsp;Satomi Kobayashi,&nbsp;Hiroaki Hatano,&nbsp;Saeko Yamada,&nbsp;Masahiro Nakano,&nbsp;Ryochi Yoshida,&nbsp;Mineto Ota,&nbsp;Yumi Tsuchida,&nbsp;Yasuo Nagafuchi,&nbsp;Kenichi Shimane,&nbsp;Ken Yoshida,&nbsp;Daitaro Kurosaka,&nbsp;Shuji Sumitomo,&nbsp;Hirofumi Shoda,&nbsp;Kazuhiko Yamamoto,&nbsp;Tomohisa Okamura,&nbsp;Keishi Fujio","doi":"10.1002/acr2.11521","DOIUrl":"https://doi.org/10.1002/acr2.11521","url":null,"abstract":"<p><strong>Objective: </strong>Idiopathic inflammatory myopathies (IIM) demonstrate characteristic clinical phenotypes depending on the myositis-specific antibody (MSAs) present. We aimed to identify common or MSA-specific immunological pathways in different immune cell types from peripheral blood by transcriptome analysis.</p><p><strong>Methods: </strong>We recruited 33 patients with IIM who were separated into the following groups: 15 patients with active disease at onset and 18 with inactive disease under treatment. All patients were positive for MSAs: anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab) in 10 patients, anti-Mi-2 Ab in 7, and anti-aminoacyl-transfer RNA synthetase (ARS) Ab in 16. The patients were compared with 33 healthy controls. Twenty-four immune cell types sorted from peripheral blood were analyzed by flow cytometry, RNA sequencing, and differentially expressed gene analysis combined with pathway analysis.</p><p><strong>Results: </strong>The frequencies of memory B cell types were significantly decreased in active patients, and the frequency of plasmablasts was prominently increased in active patients with anti-MDA5 Ab in comparison with healthy controls. The expression of type I interferon (IFN)-stimulated genes of all immune cell types was increased in the active, but not inactive, patients. Endoplasmic reticulum stress-related genes in all IIM memory B cells and oxidative phosphorylation-related genes in inactive IIM double negative B cells were also increased, suggesting prominent B cell activation in IIM. Furthermore, active patients with anti-MDA5 Ab, anti-Mi-2 Ab, or anti-ARS Ab were distinguished by IFN-stimulated and oxidative phosphorylation-related gene expression in plasmablasts.</p><p><strong>Conclusion: </strong>Unique gene expression patterns in patients with IIM with different disease activity levels and MSA types suggest different pathophysiologies. Especially, B cells may contribute to common and MSA-specific immunological pathways in IIM.</p>","PeriodicalId":7084,"journal":{"name":"ACR Open Rheumatology","volume":"5 2","pages":"93-102"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/64/ACR2-5-93.PMC9926062.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10792439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subclinical Systemic Sclerosis Primary Heart Involvement by Cardiovascular Magnetic Resonance Shows No Significant Interval Change.","authors":"Raluca B Dumitru, Lesley-Anne Bissell, Bara Erhayiem, Graham Fent, Ananth Kidambi, Giuseppina Abignano, John P Greenwood, John Biglands, Francesco Del Galdo, Sven Plein, Maya H Buch","doi":"10.1002/acr2.11515","DOIUrl":"10.1002/acr2.11515","url":null,"abstract":"<p><strong>Objective: </strong>Subclinical systemic sclerosis (SSc) primary heart involvement is commonly described. Whether these findings progress over time is not clear. The study aimed to investigate cardiovascular magnetic resonance (CMR) interval change of subclinical SSc primary heart involvement.</p><p><strong>Methods: </strong>Patients with SSc with no cardiovascular disease underwent two CMR scans that included T1 mapping and quantitative stress perfusion. The CMR change (mean difference) and association between CMR measures and clinical phenotype were assessed. The study had a prospective design.</p><p><strong>Results: </strong>Thirty-one patients with SSc participated, with a median (interquartile range) follow-up of 33 (17-37) months (10 [32%] in the diffuse subset, 16 [52%] with interstitial lung disease [ILD], and 11 [29%] who were Scl-70+). Four of thirty-one patients had focal late gadolinium enhancement (LGE) at visit 1; one of four had an increase in LGE scar mass between visits. Two patients showed new focal LGE at visit 2. No change in other CMR indices was noted. The three patients with SSc with increased or new LGE at visit 2 had diffuse cutaneous SSc with ILD, and two were Scl-70+. A reduction in forced vital capacity and total lung capacity was associated with a reduction in left ventricular ejection fraction (ρ = 0.413, P = 0.021; ρ = 0.335, P = 0.07) and myocardial perfusion reserve (MPR) (ρ = 0.543, P = 0.007; ρ = 0.627, P = 0.002). An increase in the N-terminal pro-brain natriuretic peptide level was associated with a reduction in MPR (ρ = -0.448, P = 0.042). Patients on disease-modifying antirheumatic drugs (DMARDs) had an increase in native T1 (mean [SD] 1208 [65] vs. 1265 [56] milliseconds, P = 0.008). No other clinically meaningful CMR change in patients receiving DMARDs or vasodilators was noted.</p><p><strong>Conclusion: </strong>Serial CMR detects interval subclinical SSc primary heart involvement progression; however, this study suggests abnormalities remain largely stable with follow-up.</p>","PeriodicalId":7084,"journal":{"name":"ACR Open Rheumatology","volume":"5 2","pages":"71-80"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/dd/ACR2-5-71.PMC9926075.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10732888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Images: Severe interstitial lung disease in Sjögren disease - What happens in the lungs? Inflammation or fibrosis?","authors":"Tobias Hoffmann,&nbsp;Nikolaus Gassler,&nbsp;Ulf Teichgräber,&nbsp;Tim Sandhaus,&nbsp;Peter Oelzner,&nbsp;Gunter Wolf,&nbsp;Alexander Pfeil","doi":"10.1002/acr2.11516","DOIUrl":"https://doi.org/10.1002/acr2.11516","url":null,"abstract":"The patient, a 66-year-old woman, was fi rst diagnosed with idiopathic pulmonary fi brosis (IPF) in 2015, and therapy with nintedanib was initiated. In 2020, the patient presented to our clinic for differential diagnosis. The laboratory tests revealed an elevated antinuclear antibody titer as well as anti-Ro/SSA and anti-La/SSB antibodies. Lip mucosal biopsy revealed fi ndings of lymphoplasma cellular in fi ltration of the salivary glands consistent with Sjögren disease (SD) ( A-1 and A-2 ). High-resolution computed tomography (HRCT) of the lungs showed marked bronchiectasis, subpleural and basal reticulations, and peripherally basally accentuated ground-glass opacities, but no signi fi cant honeycombing ( B-1 and B-2 ). According to the international IPF guideline, the pattern could be classi fi ed as “ probable usual interstitial pneumonia (UIP) ” (1,2). Because of the patient ’ s poor general health condition, an invasive diagnostic was not possible. Based on these fi ndings, the diagnosis of SD with severe interstitial lung disease (ILD), not responding to nintedanib, was con fi rmed. We then initiated an immunosuppressive induction therapy with cyclophosphamide and glucocorticoids, followed by a switch to mycophenolate mofetil. Due to the rapid and severe pulmonary deterioration, a single lung transplantation was performed. Microscopically, the central and peripheral lung parenchyma revealed a patchy fi brous proliferation with an extensive fi brosis pattern and lymphohistiocytic in fi ltration, especially peripheral with","PeriodicalId":7084,"journal":{"name":"ACR Open Rheumatology","volume":"5 2","pages":"61-62"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/2e/ACR2-5-61.PMC9926058.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10732351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selective Inhibition of the MK2 Pathway: Data From a Phase IIa Randomized Clinical Trial in Rheumatoid Arthritis.","authors":"David Gordon,&nbsp;Alan Kivitz,&nbsp;Atul Singhal,&nbsp;David Burt,&nbsp;Madison C Bangs,&nbsp;Emma E Huff,&nbsp;Heidi Rath Hope,&nbsp;Joseph B Monahan","doi":"10.1002/acr2.11517","DOIUrl":"https://doi.org/10.1002/acr2.11517","url":null,"abstract":"<p><strong>Objective: </strong>The study objective was to evaluate the safety, tolerability, pharmacodynamics, and preliminary efficacy of ATI-450 with methotrexate in patients with rheumatoid arthritis (RA).</p><p><strong>Methods: </strong>A parallel-assignment, placebo-controlled, investigator-blinded/patient-blinded multicenter study evaluated patients with moderate-to-severe RA aged 18 to 70 years. Eligible patients were randomized (1:1) to ATI-450 50-mg oral tablets twice daily or placebo with a stable weekly dose of methotrexate for 12 weeks. The primary objective was to assess ATI-450 safety and tolerability. The secondary objectives were to assess the median percentage change from baseline high-sensitivity C-reactive protein (hs-CRP) levels, the mean change from baseline in Disease Activity Score in 28 joints based on CRP level (DAS28-CRP) and Rheumatoid Arthritis Magnetic Resonance Imaging Score hand-wrist assessments of synovitis or bone erosion at week 12, and the proportion of patients with American College of Rheumatology 20/50/70 (ACR 20/50/70) and with DAS28-CRP scores of less than 2.6. The exploratory outcomes were change from baseline in endogenous and ex vivo-stimulated cytokine levels.</p><p><strong>Results: </strong>ATI-450 was well tolerated with no severe adverse events reported. ATI-450 reduced median hs-CRP levels by 42% or more at all posttreatment timepoints. In the ATI-450 group, a mean (median) decrease in DAS28-CRP score of 2.0 (2.1) was observed at week 12; proportions of patients with an ACR 20/50/70 response in the per-protocol population were 60%, 33%, and 20%, respectively, at week 12. Endogenous plasma levels of key inflammatory cytokines (tumor necrosis factor α, macrophage inflammatory protein 1β, interleukin 6, interleukin 8) were reduced across the 12 treatment weeks.</p><p><strong>Conclusion: </strong>This is the first clinical study demonstrating that selective mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (MK2) pathway blockade leads to a sustained antiinflammatory effect. This suggests that targeting the MK2 pathway mitigates the tachyphylaxis observed with p38 MAPK inhibitors in RA and supports further exploration.</p>","PeriodicalId":7084,"journal":{"name":"ACR Open Rheumatology","volume":"5 2","pages":"63-70"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/12/ACR2-5-63.PMC9926068.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10732882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Giant Cell Arteritis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments.","authors":"","doi":"10.1002/acr2.11519","DOIUrl":"https://doi.org/10.1002/acr2.11519","url":null,"abstract":"This paper by Dua and colleagues (ACR open rheumatology, 3(7), 429–441. https://doi.org/10.1002/acr2. 11226, published 02 April 2021) has been corrected to account for an error in the data abstraction regarding the use of ultrasound in the diagnosis of giant cell arteritis (GCA). Some studies informing this question were missed in error and not analyzed after being included in the full text screening of the articles (Table 1). When the test accuracy results from the missing studies were used, the estimated pooled sensitivity for temporal ultrasound was 0.62 (0.43; 0.77) and specificity was 0.85 (0.76, 0.91) when compared with temporal artery biopsy histology. These findings are illustrated in figure 1 and 2. This correction does not change the findings of the original publication as the prior reported results showed that the test accuracy of a halo sign on ultrasound for diagnosing GCA showed a sensitivity of 40% to 67% and a specificity","PeriodicalId":7084,"journal":{"name":"ACR Open Rheumatology","volume":"5 2","pages":"81-83"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/c5/ACR2-5-81.PMC9926063.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10736976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}